Novel Strategy for Treating Castration-Resistant Prostate Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (15 March 2022) | Viewed by 57420
Special Issue Editors
Interests: prostate cancer; uro-oncology; biomarkers; targeted therapy; precision medicine; molecular epidemiology
Special Issues, Collections and Topics in MDPI journals
Interests: prostate cancer; natural product research; inflammasome; miRNA; precision medicine
Special Issue Information
Dear Colleagues,
Prostate cancer is the most frequently diagnosed cancer among men. Androgen deprivation therapy (ADT) has emerged as a first-line therapy for initial management of advanced or metastatic prostate cancer; however, many patients eventually develop castration-resistant prostate cancer (CRPC) and distant metastasis, accounting for the majority of the mortality from the prostate cancer. Although several new options for the treatment of metastatic CRPC (mCRPC) have been approved in the last few years: the CYP17 inhibitor abiraterone, the androgen receptor (AR) antagonist enzalutamide, the taxane cabazitaxel, the immunotherapy sipuleucel-T and the alpha-emmitter radium-223 for men with bone metastases, CRPC remains incurable. To improve the therapeutic efficacy of CRPC or develop a novel therapeutic agent is urgently needed. This Special Issue of Biomedicines, entitled “Novel strategy for treating castration-resistant prostate cancer,” will include reviews that describe novel strategies for treating CRPC developed over the past few years as well as original research articles that describe novel strategies for treating CRPC using preclinical and/or translational studies. In addition, studies in combination therapy, drug response, tumor microenvironment, and mechanistic approaches will be accepted.
Prof. Dr. Shu-Pin Huang
Dr. Chia-Yang Li
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- hormonal therapy
- chemotherapy
- immunotherapy
- natural bioactive products
- targeted therapies
- biomarkers
- precision medicine
- tumor microenvironment
- cancer stem cells
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.